OpenSAFELY: The impact of COVID-19 on azathioprine, leflunomide, and methotrexate monitoring, and factors associated with change in monitoring rate
Data Availability
All data were linked, stored and analysed securely within the OpenSAFELY platform https://opensafely.org/. All code is shared openly for review and re-use under MIT open license. Detailed pseudonymised patient data is potentially re-identifiable and therefore not shared. We rapidly delivered the OpenSAFELY data analysis platform without prior funding to deliver timely analyses on urgent research questions in the context of the global Covid-19 health emergency: now that the platform is established we are developing a formal process for external users to request access in collaboration with NHS England; details of this process are available at [OpenSAFELY.org](http://opensafely.org/). All clinical and medicines codelists are openly available for inspection and reuse at https://codelists.opensafely.org/.
Subject Area
- Addiction Medicine (397)
- Allergy and Immunology (708)
- Anesthesia (200)
- Cardiovascular Medicine (2911)
- Dermatology (249)
- Emergency Medicine (438)
- Epidemiology (12687)
- Forensic Medicine (10)
- Gastroenterology (825)
- Genetic and Genomic Medicine (4546)
- Geriatric Medicine (413)
- Health Economics (723)
- Health Informatics (2901)
- Health Policy (1067)
- Hematology (383)
- HIV/AIDS (920)
- Medical Education (422)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4313)
- Nursing (233)
- Nutrition (633)
- Oncology (2253)
- Ophthalmology (641)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (277)
- Palliative Medicine (83)
- Pathology (496)
- Pediatrics (1193)
- Primary Care Research (492)
- Public and Global Health (6901)
- Radiology and Imaging (1519)
- Respiratory Medicine (913)
- Rheumatology (435)
- Sports Medicine (381)
- Surgery (483)
- Toxicology (60)
- Transplantation (209)
- Urology (178)